Key facts
- Nanocan Therapeutics’s last known valuation is $24.0M (Feb 2025).
- It has raised $6.4M across 1 recorded rounds; the latest was Early Stage VC ($5.1M) in Dec 2022.
- Notable investors include National Institutes of Health, Sand Hill Angels, Lifeforce Capital, AIN Ventures, Alliance of Angels — 7 tracked in total.
- Nanocan Therapeutics has filed 1 Form D with the SEC, most recently Feb 2025 ($5.1M sold to 41 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Nanocan Therapeutics
Funding rounds
1 roundsAbout Nanocan Therapeutics
Developer of a novel drug-delivery nanotechnology designed for patients targeting certain solid cancer indications. The company's technology offers a sustained release of therapeutic agents, including immunotherapy, chemotherapy, and phytomedicines that enhance efficacy, minimize adverse effects, and optimize patient outcomes, enabling healthcare providers to deliver effective and accessible treatments to patients.
- Sector
- Healthcare
- HQ
- National Harbor, MD, United States
- Founded
- 2020
- Employees
- 9
- Website
- nanocan.life/
- Ownership
- Privately Held (backing)
Nanocan Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nanocan Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nanocan Therapeutics in its N-PORT filings yet. We sweep new filings monthly.